Explore Fate Therapeutics' pipeline, financials, and market position to assess if its 75% drop reflects true value or ...

A Beachwood-based biotechnology company has secured $20 million in financing that will enable an expansion in personnel, ...

Stem cell-derived pancreatic islets are being studied as a rich transplantable source for insulin production, a therapeutic ...

Developed at the Children's Hospital of Philadelphia (CHOP) and called Zynteglo, the medicine uses the patient's own stem ...

Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning ...

Apr. 25, 2025 — Chimpanzee naive pluripotent stem cells (PSCs) can now be grown in cellular cultures, reveals a recent study. They successfully created chimpanzee early embryo models ...

Cambridge, Massachusetts– (Newsfile Corp. – May 8, 2025) – Ernexa Therapeutics (NASDAQ: ERNA), today announced its ...

The potential of big data analytics (BDA) to transform the prevention, diagnosis, and treatment of cardiovascular diseases ...

April 29, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment ...

Ernexa Therapeutics (Nasdaq: ERNA) is developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune disease. Ernexa's core technology focuses on engineering induced ...